MedWatch

GN Group stock is under pressure, says analyst

A Sydbank analyst explains why the hearing aid and audio group has been sliding down Denmark’s biggest trading index in the past few days.

Photo: GN Store Nord / PR

GN Group, which manufactures hearing aids under its GN Hearing arm, is facing headwinds on the Copenhagen stock exchange, as the company’s share price has dropped 16.3% over the course of five days.

On Friday, GN scraped the bottom of the C25 index, which lists the 25 largest and most traded shares on the Copenhagen exchange, with a stock price plummet of 7.3%.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs